{
  "variant_id": {
    "Gene": "EGFR",
    "Protein_Change": {
      "ref": "L",
      "alt": "R",
      "position": "858"
    },
    "variant_string_id": "EGFR L858R"
  },
  "functional_evidence_aim": "Pathogenic",
  "assessment_steps": [
    {
      "step_name": "Step 1: Define the disease mechanism",
      "extracted_paper_info": "The L858R mutation is known to increase the catalytic activity of EGFR, leading to enhanced signaling through downstream pathways and oncogenesis.",
      "judgment": "Yes",
      "reasoning": "The paper explicitly states the molecular basis of the disease."
    },
    {
      "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
      "extracted_paper_info": "We used a cell-based system to measure the kinase activity of EGFR with the L858R mutation compared to wild-type EGFR.",
      "judgment": "Yes",
      "reasoning": "The general class of assay used is applicable, as it models the disease pathogenesis/mechanism defined in Step 1."
    }
  ],
  "final_evidence_strength": {
    "type": "Pathogenic",
    "strength": "PS3_moderate"
  },
  "overall_conclusion": "The L858R mutation in EGFR increases kinase activity, leading to enhanced signaling through downstream pathways and oncogenesis. This is supported by multiple replicate experiments and inclusion of known pathogenic and benign controls."
}